ClinicalTrials.gg
Not yet recruitingNCT07851844POLYFRAUpdated Oct 1, 2026

Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France

An observational study in Genetic and Inflammatory Polyneuropathies, sponsored by Assistance Publique - Hôpitaux de Paris. Not yet recruiting at 26 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

To describe the clinical, electrophysiological, and genetic characteristics of patients with genetic and inflammatory polyneuropathies in France.

Read the detailed description

To describe the clinical, electrophysiological, and genetic characteristics of genetic and inflammatory peripheral neuropathies in detail in order to advance our understanding of these rare and disabling diseases. This detailed description is also necessary with a view to the future use of innovative treatments. In recent years, there have indeed been spectacular advances in the field of genetic therapies (siRNA, antisense oligonucleotides, gene therapy) and next-generation immunosuppressive therapies (complement inhibitors, anti-FcRN), all of which are applicable in the short- to medium-term for genetic and inflammatory polyneuropathies.

This is a multicenter, prospective-retrospective study using data collected as part of routine clinical care.The objectives are as follows:

  • Describe the different subtypes of genetic and inflammatory pyneuropathies in France
  • Describe the demographic characteristics
  • Describe the geographic distribution
  • Describe the electrophysiological findings
  • Describe the genetic abnormalities
02

Conditions studied

  • Genetic and Inflammatory Polyneuropathies

Keywords

  • Rare Diseases
  • Genetic Testing
  • Electrophysiology
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Charcot-Marie-Tooth Disease
  • Inflammatory Neuropathy
  • Hereditary Neuropathy
  • Polyneuropathy
03

In context

Neuritis

73 studies on the registry are indexed under Neuritis; 20 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 123 across 20 observational studies indexed under Neuritis.

Browse Neuritis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults diagnosed with genetic or inflammatory polyneuropathy and followed in participating neurology centers in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged 18 years or older.
  • Patients with a diagnosis of genetic or inflammatory polyneuropathy, confirmed by complementary examinations performed as part of routine care, including genetic, biological and/or electrophysiological tests.

Exclusion criteria

Exclusion Criteria:

- Patient opposition to the use of their routine care data for research purposes.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Number and percentage of participants by type of polyneuropathy

    Participants will be classified as having genetic or inflammatory polyneuropathy according to the diagnosis documented in their medical records. The number and percentage of participants in each category will be reported.

    Time frame: At inclusion, based on the diagnosis documented in the medical record.

Secondary outcomes

  1. Number and percentage of participants by polyneuropathy subtype

    The number and percentage of participants in each genetic or inflammatory polyneuropathy subtype, as documented in the medical records, will be reported.

    Time frame: At inclusion, based on the diagnosis documented in the medical record.

  2. Demographic characteristics of patients

    Description of demographic characteristics of patients with genetic or inflammatory polyneuropathies, including age, sex and other available demographic data.

    Time frame: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.

  3. Geographical distribution of patients

    Description of the geographical distribution of patients with genetic or inflammatory polyneuropathies included in participating centers in France.

    Time frame: At baseline, corresponding to the date of inclusion in the study, using data available in the medical record up to that date.

  4. Number and percentage of participants by electrophysiological neuropathy pattern

    The electrophysiological neuropathy pattern documented in the medical record will be classified as axonal, demyelinating or mixed. The number and percentage of participants in each category will be reported.

    Time frame: At inclusion, based on electrophysiological examinations available in the medical record.

  5. Genetic abnormalities

    Description of genetic abnormalities identified in patients with genetic or inflammatory polyneuropathies, when genetic analysis results are available in the medical records.

    Time frame: At baseline, corresponding to the date of inclusion in the study, using genetic data available in the medical record up to that date.

07

Study locations

26 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Nov 2036, 120 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Oct 1, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Nov 1, 2036
CompletionEst.
Nov 1, 2036
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07851844
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Nov 1, 2036 (estimated)
Completion
Nov 1, 2036 (estimated)
Last update
Oct 1, 2026

Study contacts

Andoni ECHANIZ-LAGUNA
Contact
andoni.echaniz-laguna@aphp.fr
+33(0)145212677

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion